AP
ALDR

AHL Partners’s Alder Biopharmaceuticals ALDR Stock Holding History

AHL Partners’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-15,649
Closed -$512K – 1256
2016
Q3 		$512K Buy
+15,649
New +$477K 0.02% 831

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

AHL Partners's ALDR Position: Q4 2016 in Review

AHL Partners sold out of Alder Biopharmaceuticals (ALDR) in Q4 2016, closing a stake of 15,649 shares — an estimated $512K sold.

AHL Partners first reported a position in ALDR in Q3 2016 and held it in 1 quarter. The position peaked at $512K in Q3 2016. 145 funds tracked by Wall St. Rank hold ALDR as of Q4 2016.

  • AHL Partners reported no remaining Alder Biopharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • AHL Partners sold 15,649 Alder Biopharmaceuticals shares in Q4 2016, an estimated $512K.
  • AHL Partners first reported a position in Alder Biopharmaceuticals in Q3 2016 and held it in 1 quarter.
  • AHL Partners's Alder Biopharmaceuticals position peaked at $512K in Q3 2016.
  • 145 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2016.

Based on AHL Partners's 13F filing for Q4 2016, filed 14 Feb 2017.